1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
17
Citations
NaN
KQI